Medtronic Gains CE Mark Approval for BrainSense Adaptive DBS, Advancing Parkinson's Treatment in Europe and UK
MDTJanuary 13, 2025
Read more →Looking Into Medtronic's Recent Short Interest
MDTDecember 24, 2024
Read more →Bernstein Maintains Outperform on Medtronic, Raises Price Target to $97
MDTNovember 20, 2024
Read more →Wells Fargo Maintains Overweight on Medtronic, Lowers Price Target to $98
MDTNovember 20, 2024
Read more →Medtronic Receives FDA Clearance For New InPen App, Paving The Way For Its Smart MDI System Launch With Simplera CGM
MDTNovember 20, 2024
Read more →Baird Maintains Neutral on Medtronic, Lowers Price Target to $93
MDTNovember 20, 2024
Read more →Needham Reiterates Hold on Medtronic
MDTNovember 20, 2024
Read more →Nasdaq Gains 1% Ahead Of Nvidia Earnings: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone
MDTNovember 20, 2024
Read more →Medtronic Q2 Earnings: Diabetes And Neuroscience Revenue Boost Growth, Raises Annual Outlook
MDTMedtronic Q2 2025 revenue hits $8.4 billion with 5.3% YoY growth. Raised FY25 organic revenue growth guidance to 4.75%-5% amid solid segment gains.
November 19, 2024
Read more →Medtronic shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales and raised its FY25 guidance.
MDTNovember 19, 2024
Read more →Medtronic Raised Its Fy25 Adjusted EPS Guidance To $5.44-$5.50 Versus The Prior $5.42-$5.50 And Consensus Of $5.45
MDTNovember 19, 2024
Read more →Medtronic Raised Its FY25 Organic Revenue Growth Guidance To 4.75%-5% Versus The Prior Range Of 4.5%-5%
MDTNovember 19, 2024
Read more →Medtronic Q2 2025 Adj EPS $1.26 Beats $1.25 Estimate, Sales $8.40B Beat $8.27B Estimate
MDTNovember 19, 2024
Read more →Earnings Preview For Medtronic
MDTNovember 18, 2024
Read more →Analyst Expectations For Medtronic's Future
MDTNovember 18, 2024
Read more →Needham Reiterates Hold on Medtronic
MDTNovember 18, 2024
Read more →CMS grants Transitional Pass-Through Payment For Medtronic Symplicity Spyral Renal Denervation Catheter; Will Be Effective For Up To Three Years Beginning January 1, 2025
MDTNovember 1, 2024
Read more →Medtronic's Heart Catheter Achieves Safety And Efficacy Goals In Patients With Irregular Heartbeat
MDTMedtronic's SPHERE Per-AF study results reveal the Sphere-9 Catheter's superior safety and efficacy in treating persistent atrial fibrillation compared to the Thermocool SmartTouch SF. The Sphere-9 offers advanced mapping and ablation, showing higher freedom from AFib and fewer complications.
May 20, 2024
Read more →Medtronic Affera Mapping And Ablation System With Sphere-9 Catheter Achieves Endpoints For Safety And Efficacy
MDTMay 17, 2024
Read more →Medtronic Unusual Options Activity
MDTMay 17, 2024
Read more →Medtronic Presented Late-Breaking Data Showing Performance Of Its OmniaSecure Defibrillation Lead Met Its Primary Safety And Effectiveness Endpoints, Exceeding Prespecified Performance Goals, In The Global LEADR Pivotal Trial
MDTMay 17, 2024
Read more →Titan Medical Announced Definitive Agreement with Medtronic Comprising a Limited Development Program
MDTSeptember 12, 2022
Read more →Ra Medical Systems Announced Definitive Merger Agreement with Catheter Precision; Merger Structured as Stock for Stock Reverse Merger
MDTSeptember 12, 2022
Read more →Titan Medical Announces Receipt Of A $2.6M Purchase Order From Medtronic
MDTMay 3, 2022
Read more →